Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints

Eric A. Macklin, Deborah Blacker, Bradley T. Hyman, Rebecca Betensky

Research output: Contribution to journalArticle

Abstract

Alzheimer's disease (AD) trials initiated during or before the prodrome are costly and lengthy because patients are enrolled long before clinical symptoms are apparent, when disease progression is slow. We hypothesized that design of such trials could be improved by: 1) selecting individuals at moderate near-term risk of progression to AD dementia (the current clinical standard) and 2) by using short-term surrogate endpoints that predict progression to AD dementia. We used a longitudinal cohort of older, initially non-demented, community-dwelling participants (n = 358) to derive selection criteria and surrogate endpoints and tested them in an independent national data set (n = 6,243). To identify a 'mid-risk' subgroup, we applied conditional tree-based survival models to Clinical Dementia Rating (CDR) scale scores and common neuropsychological tests. In the validation cohort, a time-to-AD dementia trial applying these mid-risk selection criteria to a pool of all non-demented individuals could achieve equivalent power with 47% fewer participants than enrolling at random from that pool. We evaluated surrogate endpoints measureable over two years of follow-up based on cross-validated concordance between predictions from Cox models and observed time to AD dementia. The best performing surrogate, rate of change in CDR sum-of-boxes, did not reduce the trial duration required for equivalent power using estimates from the validation cohort, but alternative surrogates with better ability to predict time to AD dementia should be able to do so. The approach tested here might improve efficiency of prodromal AD trials using other potential measures and could be generalized to other diseases with long prodromal phases.

Original languageEnglish (US)
Pages (from-to)475-486
Number of pages12
JournalJournal of Alzheimer's Disease
Volume36
Issue number3
DOIs
StatePublished - Jan 1 2013

Fingerprint

Alzheimer Disease
Biomarkers
Patient Selection
Dementia
Independent Living
Aptitude
Neuropsychological Tests
Proportional Hazards Models
Disease Progression
Efficiency
Survival

Keywords

  • Alzheimer's disease
  • clinical trials as topic
  • National Alzheimer's Coordinating Center Uniform Data Set
  • surrogate endpoint
  • survival analysis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints. / Macklin, Eric A.; Blacker, Deborah; Hyman, Bradley T.; Betensky, Rebecca.

In: Journal of Alzheimer's Disease, Vol. 36, No. 3, 01.01.2013, p. 475-486.

Research output: Contribution to journalArticle

@article{331effb4c859457a9cd2c33f8df6ab41,
title = "Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints",
abstract = "Alzheimer's disease (AD) trials initiated during or before the prodrome are costly and lengthy because patients are enrolled long before clinical symptoms are apparent, when disease progression is slow. We hypothesized that design of such trials could be improved by: 1) selecting individuals at moderate near-term risk of progression to AD dementia (the current clinical standard) and 2) by using short-term surrogate endpoints that predict progression to AD dementia. We used a longitudinal cohort of older, initially non-demented, community-dwelling participants (n = 358) to derive selection criteria and surrogate endpoints and tested them in an independent national data set (n = 6,243). To identify a 'mid-risk' subgroup, we applied conditional tree-based survival models to Clinical Dementia Rating (CDR) scale scores and common neuropsychological tests. In the validation cohort, a time-to-AD dementia trial applying these mid-risk selection criteria to a pool of all non-demented individuals could achieve equivalent power with 47{\%} fewer participants than enrolling at random from that pool. We evaluated surrogate endpoints measureable over two years of follow-up based on cross-validated concordance between predictions from Cox models and observed time to AD dementia. The best performing surrogate, rate of change in CDR sum-of-boxes, did not reduce the trial duration required for equivalent power using estimates from the validation cohort, but alternative surrogates with better ability to predict time to AD dementia should be able to do so. The approach tested here might improve efficiency of prodromal AD trials using other potential measures and could be generalized to other diseases with long prodromal phases.",
keywords = "Alzheimer's disease, clinical trials as topic, National Alzheimer's Coordinating Center Uniform Data Set, surrogate endpoint, survival analysis",
author = "Macklin, {Eric A.} and Deborah Blacker and Hyman, {Bradley T.} and Rebecca Betensky",
year = "2013",
month = "1",
day = "1",
doi = "10.3233/JAD-122212",
language = "English (US)",
volume = "36",
pages = "475--486",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints

AU - Macklin, Eric A.

AU - Blacker, Deborah

AU - Hyman, Bradley T.

AU - Betensky, Rebecca

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Alzheimer's disease (AD) trials initiated during or before the prodrome are costly and lengthy because patients are enrolled long before clinical symptoms are apparent, when disease progression is slow. We hypothesized that design of such trials could be improved by: 1) selecting individuals at moderate near-term risk of progression to AD dementia (the current clinical standard) and 2) by using short-term surrogate endpoints that predict progression to AD dementia. We used a longitudinal cohort of older, initially non-demented, community-dwelling participants (n = 358) to derive selection criteria and surrogate endpoints and tested them in an independent national data set (n = 6,243). To identify a 'mid-risk' subgroup, we applied conditional tree-based survival models to Clinical Dementia Rating (CDR) scale scores and common neuropsychological tests. In the validation cohort, a time-to-AD dementia trial applying these mid-risk selection criteria to a pool of all non-demented individuals could achieve equivalent power with 47% fewer participants than enrolling at random from that pool. We evaluated surrogate endpoints measureable over two years of follow-up based on cross-validated concordance between predictions from Cox models and observed time to AD dementia. The best performing surrogate, rate of change in CDR sum-of-boxes, did not reduce the trial duration required for equivalent power using estimates from the validation cohort, but alternative surrogates with better ability to predict time to AD dementia should be able to do so. The approach tested here might improve efficiency of prodromal AD trials using other potential measures and could be generalized to other diseases with long prodromal phases.

AB - Alzheimer's disease (AD) trials initiated during or before the prodrome are costly and lengthy because patients are enrolled long before clinical symptoms are apparent, when disease progression is slow. We hypothesized that design of such trials could be improved by: 1) selecting individuals at moderate near-term risk of progression to AD dementia (the current clinical standard) and 2) by using short-term surrogate endpoints that predict progression to AD dementia. We used a longitudinal cohort of older, initially non-demented, community-dwelling participants (n = 358) to derive selection criteria and surrogate endpoints and tested them in an independent national data set (n = 6,243). To identify a 'mid-risk' subgroup, we applied conditional tree-based survival models to Clinical Dementia Rating (CDR) scale scores and common neuropsychological tests. In the validation cohort, a time-to-AD dementia trial applying these mid-risk selection criteria to a pool of all non-demented individuals could achieve equivalent power with 47% fewer participants than enrolling at random from that pool. We evaluated surrogate endpoints measureable over two years of follow-up based on cross-validated concordance between predictions from Cox models and observed time to AD dementia. The best performing surrogate, rate of change in CDR sum-of-boxes, did not reduce the trial duration required for equivalent power using estimates from the validation cohort, but alternative surrogates with better ability to predict time to AD dementia should be able to do so. The approach tested here might improve efficiency of prodromal AD trials using other potential measures and could be generalized to other diseases with long prodromal phases.

KW - Alzheimer's disease

KW - clinical trials as topic

KW - National Alzheimer's Coordinating Center Uniform Data Set

KW - surrogate endpoint

KW - survival analysis

UR - http://www.scopus.com/inward/record.url?scp=84881473829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881473829&partnerID=8YFLogxK

U2 - 10.3233/JAD-122212

DO - 10.3233/JAD-122212

M3 - Article

VL - 36

SP - 475

EP - 486

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 3

ER -